GLUE
Monte Rosa Therapeutics
$22.56
−$0.22 (−0.97%)Jul 27, 2026
Key metrics
The numbers that frame GLUE today
- Market cap
- $1.91B
- P/E (TTM)
- -14.7
- EV / FCF
- -90.6
- Gross margin
- 100%
- EV / Sales
- 41.4
- ROIC
- -39.4%
- Div yield
- 0%
- Debt / equity
- 0.1
- 52wk Low
- $4.12
- 52wk High
- $25.77
Growth
Revenue and earnings trend for GLUE
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about GLUE
Is Monte Rosa Therapeutics a good buy?
Hold. Monte Rosa Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks poor. That could put pressure on the long-term business case. We think Monte Rosa Therapeutics is selling at a high price.
What is the market capitalization of GLUE?
Monte Rosa Therapeutics's market capitalization is $1.91B.
What is the P/E ratio for GLUE stock?
Monte Rosa Therapeutics's current P/E ratio is -14.7.
What is the 52-week high for GLUE stock?
The 52-week high for Monte Rosa Therapeutics is $25.77. The current close of $22.56 is 12.5% below that high.
What is the 52-week low for GLUE stock?
The 52-week low for Monte Rosa Therapeutics is $4.12. The current close of $22.56 is 447.6% above that low.
Does GLUE stock pay dividends?
Monte Rosa Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for GLUE?
Monte Rosa Therapeutics's Debt / Equity ratio is 0.08.